CAS 1654725-02-6

N-[3-(Aminocarbonyl)-4,7-dihydro-5,5,7,7-tetramethyl-5H-thieno[2,3-c]pyran-2-yl]-1H-pyrazole-3-carboxamide

CAS : 1654725-02-6

Formule : C₁₆H₂₀N₄O₃S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 348.4200

Ref: IN-DA01EOIM

N-(3-Carbamoyl-5,5,7,7-Tetramethyl-5,7-Dihydro-4H-Thieno[2,3-c]Pyran-2-Yl)-1H-Pyrazole-3-Carboxamide

CAS : 1654725-02-6

N-(3-Carbamoyl-5,5,7,7-Tetramethyl-5,7-Dihydro-4H-Thieno[2,3-c]Pyran-2-Yl)-1H-Pyrazole-3-Carboxamide

Formule : C₁₆H₂₀N₄O₃S

Degré de pureté : 99%

Masse moléculaire : 348.42

Ref: 54-OR1025801

GLPG1837

CAS : 1654725-02-6

GLPG1837

Formule : C₁₆H₂₀N₄O₃S

Degré de pureté : ≥98%

Masse moléculaire : 348.42

Ref: 54-BUP15197

GLPG1837

CAS : 1654725-02-6

GLPG1837 (ABBV-974) is an effective CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively.

Formule : C₁₆H₂₀N₄O₃S

Degré de pureté : 99.64% - 99.91%

Couleur et forme : Solid

Masse moléculaire : 348.42

Ref: TM-T7083

GLPG 1837

CAS : 1654725-02-6

GLPG 1837 is a small molecule potentiator, which is derived from a synthetic compound designed to target cystic fibrosis transmembrane conductance regulator (CFTR) protein variants. The source of GLPG 1837 is based on medicinal chemistry approaches focused on optimizing interactions with CFTR. The mode of action involves enhancing the channel gating of the CFTR protein, specifically addressing defects in CFTR function by increasing the probability of the channel being open and facilitating chloride ion transport across cell membranes.

Formule : C₁₆H₂₀N₄O₃S

Degré de pureté : Min. 95%

Masse moléculaire : 348.42 g/mol

Ref: 3D-ERC72502